Clinical trials: Contraceptive Devices
Contraception
A Study of Oral Contraception Under Simulated OTC Conditions
This study is designed to assess whether consumers select and use norgestrel 0.075 mg, a progestin only pill for contraception, in a manner consistent with the OTC package directions in an Over-the-Counter (OTC)-like setting.
- Trial name
- OPTION (NCT03559010)
- Testing
- Norgestrel 0.075 mg tablets
- Where
- 44 sites in United States
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pelvic Pain Associated With Refractory Endometriosis
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis
The purpose of this study is to determine efficacy, safety, tolerability and pharmacokinetics of multiple doses of BGS649 with concurrent daily administration of combined oral contraception in patients with refractory…
- Trial name
- NCT01116440
- Testing
- BGS649
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Mereo BioPharma
Oral Contraceptive
Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition
The aim of this monocenter, open-label, randomized study is to determine the ovulation inhibitory effect of the combined oral contraceptive (COC) SH T04769G and to collect supplementary data regarding the ovulation inhibitory…
- Trial name
- NCT00471991
- Testing
- SH T04769G, Ethinyl estradiol / dienogest (SH D00659 AF)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bayer
Contraception, Female Contraception
Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
The purpose of the study is to evaluate user experience with the EVRA® Contraceptive Transdermal Patch; specifically, user satisfaction with the EVRA® Patch, and if applicable, user preference of the EVRA® Patch compared with…
- Trial name
- NCT00261482
- Testing
- norelgestromin + ethinyl estradiol
- Volunteers
- 778 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Removal of a Contraceptive Subdermal Implant
Safe Access: Trial With RemovAid Device
This randomized trial will compare different approaches to removing a subdermal contraceptive implant from the upper arm of 225 women in Uganda.
- Trial name
- NCT04120337
- Testing
- RemovAid device + lidocaine patch, Standard technique + lidocaine injection, RemovAid device + lidocaine injection
- Where
- Uganda
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- RemovAid AS
Diabetes Mellitus, Type 2
An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .
This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon).
- Trial name
- NCT01077505
- Testing
- albiglutide, Oral contraceptive (Brevicon)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hemostasis, Oral Contraceptive
A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women
This study is being conducted to evaluate the impact of DR-102, a 28-day oral contraceptive compared to a standard 28-day oral contraceptive regimen on hemostatic parameters in healthy women.
- Trial name
- NCT01388491
- Testing
- desogestrel/ethinyl estradiol and ethinyl estradiol, desogestrel/ethinyl estradiol
- Where
- 27 sites in Germany, Israel and 2 more
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Healthy
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers
The purpose of this study is to investigate whether there is a drug-drug interaction between multiple doses of canagliflozin (JNJ-28431754) and single doses of an oral contraceptive containing ethinyl estradiol and…
- Trial name
- NCT01714193
- Testing
- Oral contraceptive, Canagliflozin (JNJ-28431754)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Infection, Human Immunodeficiency Virus
Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol
Dolutegravir (DTG, GSK1349572 is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of HIV infection. DTG will likely be used in women on oral contraceptives (OC) for birth control.
- Trial name
- NCT01498861
- Testing
- Ortho-Cyclen, Dolutegravir
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Dysmenorrhea
Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea
The purpose of this study is to determine whether combination oral contraceptive pill of norethindrone and ethinyl estradiol is effective in the treatment of primary dysmenorrhea.
- Trial name
- NCT00746096
- Testing
- IKH-01
- Volunteers
- 115 people
- Sponsor
- Nobelpharma
Contraceptive Usage
Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception
The purpose of this study is to determine whether NEA TDS is effective in the prevention of pregnancy. The safety of this product will also be evaluated.
- Trial name
- Simplify (NCT01140217)
- Testing
- Norethindrone Acetate
- Where
- 53 sites in United States
- Volunteers
- 1,659 people, healthy volunteers welcome
- Sponsor
- Watson Pharmaceuticals
HIV
Condom Performance in a Longitudinal Enhanced Assessment of User Experiences
This study will enroll 252 men who have sex with men (MSM) and 252 men who have sex with women (MSW) in a double-blind, three-way randomized crossover trial with conditions of fitted, thin, and standard condoms.
- Trial name
- C-PLEASURE (NCT02753842)
- Testing
- 5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms
- Volunteers
- 504 people, healthy volunteers welcome
- Sponsor
- Global Protection Corp.
Oral Contraceptive
Comparative Trial in Hormone Withdrawal Associated Symptoms
This clinical research study will examine whether an oral contraceptive pill taken with a monthly hormone-free interval of 4 days reduces hormone withdrawal associated symptoms compared to an oral contraceptive pill taken with a…
- Trial name
- NCT01076582
- Testing
- EE20/DRSP (YAZ, BAY86-5300), Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)
- Where
- 44 sites in Argentina, Chile and 12 more
- Volunteers
- 592 people
- Sponsor
- Bayer
Change in Bone Mineral Density, Bone Loss
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
The primary objective of this study is to evaluate the impact of LF111 and drospirenone (DRSP) 3.5 mg chewable tablets on bone mineral density (BMD) at the lumbar spine after 12 months (13 medication cycles) of investigation in…
- Trial name
- NCT05303636
- Testing
- drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
- Where
- 37 sites in United States, Czechia and 1 more
- Volunteers
- 1,536 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Healthy
A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
The purpose of this study is to evaluate the effect of multiple 40 milligram (mg) doses of JNJ-42847922 on the steady state pharmacokinetics (PK) of multiple doses of a combination oral contraceptive (OC) containing ethinyl…
- Trial name
- NCT03249402
- Testing
- Ethinyl Estradiol + Levonorgestrel, JNJ-42847922
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Healthy
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is…
- Trial name
- NCT04172987
- Testing
- Tirzepatide, EE/NGM
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Primary Dysmenorrhea
SH T00186 in the Treatment of Primary Dysmenorrhea
The investigational drug SH T00186D is an oral contraceptive. The investigational drug used in this study contains the estrogen ethinylestradiol (EE) and the progestogen drospirenone (DRSP).
- Trial name
- NCT00569244
- Testing
- Drug: YAZ flex (SH T00186D), YAZ (SH T00186D)
- Where
- 27 sites in Germany, United Kingdom
- Volunteers
- 223 people
- Sponsor
- Bayer
Contraception
Investigating Ovulation Inhibition for Use as a Contraceptive
A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch
- Trial name
- NCT07365904
- Testing
- MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc